Use of the novel implantable tibial nerve stimulator, named BlueWind RENOVA iStim system, for the treatment of overactive bladder syndrome symptoms offers long-term safety with no reported technical failures, according to a recent study with a 3-year follow-up. The sustained positive impact on patient quality of life reflects the long-term efficacy of the device.
Treatment with focal high-intensity focused ultrasound (FHIFU) for patients with localized clinically significant prostate cancer is effective and safe, demonstrating acceptable oncologic and functional outcomes in the short term as well as minimal complications, according to a study, noting that patient selection is essential.
Day temperature difference appears to influence lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH), such that the greater the difference, the worse the LUTS symptoms are and the higher the tendency to visit the emergency room is, a study reports.
Treatment with 5-alpha reductase inhibitor is associated with a reduced risk of surgical intervention in men with benign prostatic hyperplasia (BPH), a recent study has shown. Patients also show high medication adherence outside of clinical trials.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).